AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAAstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to Share XAstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAhttps://pharmaphorum.com/news/astrazenecas-farxiga-gets-first-kidney-disease-ok-from-fda/
Deep Dive: Market AccessIt’s fair to say this is the most interesting time ever for market access. Not only has COVID Share XDeep Dive: Market Accesshttps://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access-2021/
Boehringer and MD Anderson extend KRAS cancer collaborationBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring Share XBoehringer and MD Anderson extend KRAS cancer collaborationhttps://pharmaphorum.com/news/boehringer-and-md-anderson-extend-kras-cancer-collaboration/
COVID-19 drives Boehringer’s R&D spend to record level in 2020Boehringer Ingelheim invested €3.7 billion on R&D last year, the highest spend in its history, as it mobilised Share XCOVID-19 drives Boehringer’s R&D spend to record level in 2020https://pharmaphorum.com/news/covid-19-drives-boehringers-rd-spend-to-record-level-in-2020/
No cooling off for pharma digital transformation in 2021COVID-19 has already proved to be a digital accelerant for the pharmaceutical industry, sparking new ideas into life Share XNo cooling off for pharma digital transformation in 2021https://pharmaphorum.com/views-analysis-digital/no-cooling-off-for-pharma-digital-transformation-in-2021/
BI investigates cancer ‘dark antigens’ with UK’s EnaraBoehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight Share XBI investigates cancer ‘dark antigens’ with UK’s Enarahttps://pharmaphorum.com/news/boehringer-to-investigate-dark-antigens-with-uk-cancer-specialist-enara/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
Boehringer buys NBE for €1.18bn, adding cancer ADC expertiseBoehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, Share XBoehringer buys NBE for €1.18bn, adding cancer ADC expertisehttps://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/
Boehringer axes IPF deal with South Korea’s Bridge Biotherapeutics over toxicity concernsBoehringer Ingelheim and South Korea’s Bridge Biotherapeutics have decided to axe their collaboration over a potential new drug Share XBoehringer axes IPF deal with South Korea’s Bridge Biotherapeutics over toxicity concernshttps://pharmaphorum.com/news/boehringer-axes-ipf-deal-with-south-koreas-bridge-therapeutics-over-toxicity-concerns/
